Stockscreener 앱 받기
0.1799
2.80%
0.0049
Oragenics Inc 주식(OGEN)의 최신 뉴스
Oragenics (NYSE:OGEN) Now Covered by Analysts at StockNews.com - Defense World
Oragenics, Inc. Announces Health and Disability Ethics Committee - GuruFocus
Oragenics, Inc. Announces Health and Disability Ethics Committee Submission for Phase IIa Concussion Trial - The Manila Times
Oragenics Announces Health And Disability Ethics Committee Submission - MarketScreener
Oragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery Summit - GlobeNewswire
Oragenics gears up for Phase II trials, appoints new CEO - MSN
Oragenics (NYSE:OGEN) Coverage Initiated at StockNews.com - Defense World
OGEN stock touches 52-week low at $0.19 amid sharp annual decline By Investing.com - Investing.com South Africa
OGEN stock touches 52-week low at $0.19 amid sharp annual decline - Investing.com
Oragenics (NYSE:OGEN) Now Covered by StockNews.com - Defense World
Oragenics reports progress in concussion drug development By Investing.com - Investing.com South Africa
OGEN stock touches 52-week low at $0.24 amid sharp annual decline By Investing.com - Investing.com South Africa
OGEN stock touches 52-week low at $0.24 amid sharp annual decline - Investing.com
Oragenics reports progress in concussion drug development - Investing.com
Oragenics Provides Q1 2025 Shareholder Update On Strategic And Financial Progress - MarketScreener
Oragenics, Inc. Provides Q1 2025 Shareholder Update on Strategic and Financial Progress - The Manila Times
Oragenics (NYSE:OGEN) Coverage Initiated by Analysts at StockNews.com - Defense World
Investornewsbreaks Oragenics Inc. Files 2024 Annual Report, Addresses Going Concern Status - MENAFN.COM
CEMATRIX To Report Fourth Quarter and 2024 Year End Results on March 26, 2025 - The Manila Times
Oragenics, Inc. Announces Filing of 2024 Annual Report on Form 10-K - TradingView
Oragenics, Inc. Files Annual Report for 2024, Receives Unqualified Audit Opinion - Nasdaq
Going Concern Alert: Oragenics Brain Treatment Pipeline Faces Critical Financial Test - StockTitan
OGEN Stock Plummets to 52-Week Low of $0.25 Amid Market Struggles - Investing.com Australia
OGEN Stock Plummets to 52-Week Low of $0.25 Amid Market Struggles By Investing.com - Investing.com South Africa
Oragenics Inc. (OGEN) reports earnings - qz.com
StockNews.com Begins Coverage on Oragenics (NYSE:OGEN) - Defense World
The Oragenics Inc (OGEN) Stock Is Headed for a Correction - US Post News
Digital Risk Inc. Launches Digital Footprint Exposure Assessment Tool to Combat Human Cybersecurity Risks - The Manila Times
Oragenics, Inc. Submits Investigator's Brochure for Phase II Clinical Trial of ONP-002 in Australia for Mild Traumatic Brain Injury - Nasdaq
Oragenics, Inc. Submits Investigator’s Brochure for Phase - GlobeNewswire
Oragenics, Inc. Submits Investigator’s Brochure for Phase II Clinical Trial of ONP-002 in Mild Traumatic Brain Injury (mTBI) - Yahoo Finance UK
Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Present at the Emergencies in Medicine Conference on Advancing Concussion Treatment - The Manila Times
Heritage Distilling Co. Cocoa Bomb Chocolate Whiskey Named 'Best Flavored Whiskey” in the United States at Whisky Magazine's World Whiskies Awards - The Manila Times
Oragenics, Inc. to Present Concussion Treatment Advancements at Emergencies in Medicine Conference - Nasdaq
Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, - GlobeNewswire
Oragenics, Inc. Chief Medical Officer, Dr. James Kelly, Joins the Medical Board of The Leigh Steinberg Foundation for Concussion, Traumatic Brain Injury, and Brain Health - The Manila Times
CytoDyn Announces Promising Survival Observations in mTNBC Patients Treated with Leronlimab - The Manila Times
Oragenics, Inc. Chief Medical Officer, Dr. James Kelly, - GlobeNewswire
5 Top AI Stocks I'm Buying on the Dip - The Globe and Mail
StockNews.com Initiates Coverage on Oragenics (NYSE:OGEN) - Armenian Reporter
Oragenics, Inc. Announces Partnership with BRAINBox - GlobeNewswire
Oragenics Partners With BRAINBox To Develop Intranasal Therapy For Concussion Treatment - Nasdaq
0.77%
0.11%
자본화:
|
볼륨(24시간):